CTLA4 and neoplasm: Third, in our in vitro tumor-killing assay, CTLA-4 and PD-1 blockade did not enhance PBMC cytotoxicity, likely due to simplified nature of the experimental system, which cannot reflect complex tumor–immune interactions in vivo.